Recent advances in allergen immunotherapy Authors: Wei Fu, Yang Zheng, Hao Chen, Xiang Dong, Wei Li, Huiling Liang, Shiwei Chen, Cezmi A Akdis, Yadong Gao Published: 2026 ABSTRACT AbstractAllergen immunotherapy (AIT) remains the only disease-modifying treatment for immunoglobulin (Ig) E-mediated allergic diseases, including allergic rhinitis (AR), asthma, food allergy, and atopic dermatitis (AD). This review provides a comprehensive update on recent advances in AIT, focusing on immunological mechanisms, novel vaccines, biomarkers, clinical outcomes across different diseases, and emerging combination strategies with biologics. We discussed the pivotal roles of regulatory T and B cells, innate lymphoid cells (ILCs), and blocking antibodies (immunoglobulin G4 [IgG4], immunoglobulin A [IgA]) in establishing long-term tolerance. Novel allergen vaccines—including recombinant and hypoallergenic derivatives, virus-like particle (VLP) conjugates, and transgenic peptide vaccines—aim to improve safety and efficacy. We critically evaluate current biomarkers for predicting and monitoring AIT response, such as the allergen-specific IgE (sIgE)/total immunoglobulin E (tIgE) ratio, basophil activation test, and cellular markers. Clinical evidence supports AIT efficacy in asthma, AR, and AD, with emerging applications in food allergies. Furthermore, combining AIT with biologics (e.g., anti-IgE and anti-interleukin [IL]-4/IL-4 receptor [IL-4R]) shows promise in enhancing safety and efficacy, particularly in severe asthma. Despite these advances, challenges remain in patient selection, treatment duration, and extract standardization. Future research should prioritize predictive biomarkers, short-course regimens, and synergistic biologic-AIT approaches. Introduction The prevalence of immunoglobulin E (IgE)-mediated allergic diseases has increased over recent decades,[1] driven by complex gene–environment interactions.[2] It is suggested that airway epithelial barrier dysfunction, caused by indoor and outdoor pollutants and allergens, contributes significantly to the pathogenesis of IgE-mediated allergic diseases.[3] Treatment options include allergen avoidance, medications, such as antihistamine drug, inhaled corticosteroids (ICS) plus long-acting β2 agonists (LABA), biologics, and allergen immunotherapy (AIT). AIT has been widely used in the treatment of IgE-mediated allergic diseases, including allergic rhinitis (AR), allergic conjunctivitis (AC), allergic asthma (AA), food allergies (FA), atopic dermatitis (AD) and venom allergy.[4] It is the only causal treatment that can modify the natural course of allergic diseases.[5] AIT can induce allergen-specific immunotolerance in sensitized patients through administration of increasing doses of vaccines, via subcutaneous immunotherapy (SCIT), sublingual immunotherapy (SLIT), or other routes.[6] Currently, aeroallergen-induced allergies, including dust mite, pollens, animal dander, and fungi, can be effectively desensitized with AIT. Although the efficacy and safety of AIT has been extensively demonstrated, it has not been widely implemented in patients with severe AA in clinical practice.[6] However, the use of biologics that target type 2 inflammation will enable more patients to achieve symptom control or partial control, making them eligible for AIT.[7] In this study, we reviewed the progress of AIT, including its underlying mechanisms, biomarkers, and outcomes. Immunological Mechanisms of AIT AIT can induce long-term immunotolerance to allergen exposure, but the underlying mechanisms are not completely clarified. Profound immunological changes have been observed during AIT [Figure 1]. Mechanism of AIT. Natural low-dose allergen exposure on damaged airway epithelium promotes DC and ILC2, which induces Th2 and Tfh cell response and release of type 2 cytokines. B cells undergo isotype switching to IgE-producing plasma cells and produce IgE under the regulation of type 2 cytokines. Tfh cells induce the development of Bmem through IL-4, IL-9, IL-21, and CD40 ligand–CD40 interaction. cTfh could share properties of memory cells. Allergen–IgE cross-linking of FcεRI receptors on MCs and basophils promotes release of granule-derived mediators such as histamine, tryptase, prostaglandin, leukotrienes and platelet activating factor. AIT induces the generation of DCreg, which stimulates ILC2 transformation to ILCreg and IL10+ ILCs, shift toward Th1 cell response, and Treg proliferation. IL-10, IL-35 and TGF-β secreted by Treg promote the differentiation of Breg cells and IgG/A producing plasma cells. Tfr cells are a subset of CXCR5+ Foxp3+ Tregs, which downregulate Tfh cell-mediated type 2 immune response. Cytokines (e.g., IL-10, IL-35, IFN-γ, CTLA-4) secreted by ILCreg, IL10+ ILCs, Treg, Breg, Th1 cells, Tfr inhibit Th2-type responses. IgG1/4 and IgA1/2 competitively inhibit allergen–IgE cross-linking to FcεRI on MCs and basophils, and IgE-facilitated antigen presentation and type 2 cell responses. Allergen-specific IgD may play a role in immune tolerance while the exact mechanism remains to be explored (with annotation of “?” mark in IgD and isotype switching of Beff). AIT: Allergen immunotherapy; BAS: Basophils; Beff: Effector B cell, or plasma cell; Bmem: Memory B cell; Bregs: Regulatory B cells; cDC2: Type-2 conventional dendritic cells; CD40L: CD40 ligand; cTfh: Circulating T follicular helper cell; cTfr: Circulating T follicular regulatory cell; CTLA-4: Cytotoxic T-lymphocyte-associated protein 4; CXCR5: C-X-C chemokine receptor type 5; DCs: Dendritic cells; DCreg: Regulatory dendritic cells; FcεRI: High-affinity IgE receptor; Foxp3: Forkhead box protein P3; iDC: Immature dendritic cells; IFN-γ: Interferon gamma; IgA: Immunoglobulin A; IgD: Immunoglobulin D; IgE: Immunoglobulin E; IgG: Immunoglobulin G; IL: Interleukin; IL-1RA: Interleukin-1 receptor antagonist; IL10+ ILC2: IL-10 producing type 2 innate lymphoid cells; ILC2: Group 2 innate lymphoid cells; ILCreg: Regulatory innate lymphoid cells; MCs: Mast cells; PD-1: Programmed cell death 1; Tfh: Follicular helper T cell; Tfr: Follicular regulatory T; TGF-β: Transforming growth factor-beta; Th1: T helper 1; Th2: T helper 2; Treg: Regulatory T cells; TSLP: Thymic stromal lymphopoietin. Adaptive immune cells are considered pivotal in the induction of immunological tolerance, with the mechanisms of T cells having been extensively characterized. More recently, regulatory cell subsets, including regulatory T cells (Tregs), regulatory B cells (Bregs), and regulatory dendritic cells (DCregs), have emerged as a central focus in the field of AIT research. AIT regulates adaptive immunity by regulating T helper 1 (Th1), inhibiting Th2 responses, and confirming an immune deviation from Th2 to Th1. AIT in patients with grass pollen allergy showed an increased apoptosis of Th2,[8] whereas Th1 cells expressed higher levels of antiapoptotic protein B-cell lymphoma 2 (bcl-2) after SLIT.[9] SCIT induces higher levels of inteferon γ (IFN-γ), Tregs and allergen-specific IgG4 (sIgG4) compared to SLIT.[10] A recent study on patients who received 3 years of house dust mite (HDM)-SCIT showed a significant decreased proportion of Th2 cells and levels of interleukin (IL)-4, IL-5 and IL-13, but not the proportions of Tregs and Th1 cells compared to untreated AA patients.[11] Consistently, a previous study showed that IL-4+, but not IFN-γ+ CD4+ and CD8+ T cells, were reduced in children after HDM-AIT.[12] Another study on changes of peripheral blood mononuclear cells (PBMC) transcriptome profile after AIT in seasonal AR patients also revealed an inhibition of Th2 and Th17 cell response and a Th1 immune deviation.[13] The induction of allergen-specific Tregs also contributes to AIT-induced specific immune tolerance to allergens.[14] Tregs are a distinct subset of CD4+ T cells that can inhibit type 2 inflammation by production of suppressive cytokines IL-10, transforming growth factor-beta (TGF-β), cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and programmed cell death protein 1 (PD-1).[15] Bee venom AIT increased IL-10 production and CD4+ CD25+ Tregs substantially early at the seventh day.[16] HDM-SLIT also significantly increased the proportion of Tregs.[17] Interestingly, AIT upregulated the activated, but downregulated the dysfunctional allergen-specific Tregs subset, suggesting that correction of dysregulated Treg responses contributes also to the effect of AIT.[14] It has been shown that grass pollen-SLIT increased allergen-driven IL-35 levels and IL-35-inducible Treg (iTr35) cell counts in seasonal AR patients.[18] Follicular helper T (Tfh) cells, rather than Th2 cells, are crucial to the regulation of IgE production.[19] Follicular regulatory T (Tfr) cells are a specialized subset of Tregs resident in B-cell follicles and regulate the interaction between B-cells and Tfh cells.[20] CD4+ C-X-C chemokine receptor type 5 (CXCR5)+ PD-1+ forkhead box protein P3 (FoxP3)+ circulating Tfr (cTfr) cells and CTLA-4+ cTfr cells significantly increased in Lolium perenne peptide-treated AR patients.[21] In addition, HDM-SCIT increased both the abundance and the suppressive capacity of cTfr cells in patients with AR.[22] Bregs are a subset of immunoregulatory B cells producing IL-10 and other anti-inflammatory molecules, including TGF-β, IL-35, PD-L1, granzyme B, CD39 and CD73, and aryl-hydrocarbon receptors.[23] Downregulated frequency and IL-10-secreting capacity of Bregs have been identified in AA patients.[24] The potential role of Bregs in allergen tolerance during AIT has been studied in both humans and animal models. AIT can induce IgG4+ Bregs that produce high levels of IL-10 and inhibit the proliferation of allergen-specific T cells.[25] IL-1 receptor antagonist (IL-1RA)+ Bregs have been characterized as the allergen-specific B cells in patients who respond well to AIT.[26] The mechanisms include IL-10-mediated suppression of Th2 responses, induction of Tregs, IL-10-mediated inhibition of dendritic cell maturation, modulation of Tfh responses, and production of anti-inflammatory IgG4 antibodies.[27] The collective actions of Tregs and Bregs result in functional changes in allergen-specific memory T and B cells, with reduced production of allergen-specific IgE (sIgE) and increased production of sIgG4, thereby increasing the activation threshold of mast cells (MCs) and basophils.[28] DCregs may also contribute to AIT-induced immune tolerance by inducing the differentiation of allergen-specific Tregs and inhibiting T cell responses.[29] Increase in the markers of DCregs has been observed in AR patients who responded well to SLIT with grass pollen tablets 2 months after the initiation of SLIT,[30] suggesting that DCregs response may be another early phase immunologic changes induced by AIT. The role of innate lymphoid cells (ILCs), monocytes and macrophages, dendritic cells (DCs), natural killer cells, and natural killer T cells in immunotolerance induced by AIT has been also extensively investigated. Innate immune cells experience long-lasting metabolic and epigenetic changes after encountering specific stimuli. This facilitates enhanced immune responses upon secondary exposure to both the same and unrelated pathogens, a process termed trained immunity.[31] AIT might induce trained immunity as a relevant mechanism contributing to the restoration of healthy immune responses to allergens. Group 2 innate lymphoid cells (ILC2s) can be activated by epithelial cell-derived alarmins such as thymic stromal lymphopoietin (TSLP), IL-33 and IL-25, and initiate adaptive type 2 immune responses.[32] AIT can inhibit the expansion of ILC2s and subsequently reduce eosinophil recruitment and type 2 cytokine production.[33] IL-10-producing ILC2s (IL-10+ ILC2s) have been identified in AR patients receiving grass pollen SLIT with functions of attenuating Th2 responses and maintaining epithelial barrier integrity.[34] Another study found that AIT induced a durable decrease in ILC2s and an increase in group 1 ILCs (ILC1s) and CD127+ CD25++ c-Kit+ group 3 ILC.[31] The changes in the composition of these cells create an immunosuppressive microenvironment contributing to immune tolerance during AIT. Type 1 DCs (DC1s) can be polarized by IL-12, IFN-γ, and IL-27 and drive the Th1 differentiation, whereas type 2 DCs (DC2s) can be induced in the presence of IL-4 and drive the differentiation of Th2 cells. The transcriptome profile studies also demonstrated a stable decrease in the expression of DC2 molecular marker, CD141, GATA binding protein 3 (GATA3), OX40 ligand, receptor-interacting serine/threonine-protein kinase 4 (RIPK4),[13,30] and increased expression of DC1 polarization cytokines IL-27 and IL-12 among the patients with good treatment outcomes following AIT.[13] NK cells are dysregulated in asthma, especially during respiratory virus-induced exacerbation of asthma.[35] The percentage of IFN-γ+ NK cells increased significantly in cat- and birch-allergic AR and AA patients after 3 weeks and 3 months of rush AIT.[36] Furthermore, AIT can induce the secretion of IL-10 by NK cells in the AD mouse model.[37] The role of NKT cells in AIT is still unknown. A study in mice models demonstrated that the activation of invariant NKT (iNKT) may protect against allergic airway inflammation through production of IL-21 and IFN-γ.[38] Interestingly, oral immunotherapy (OIT) for cow milk allergy induced a significant increase in the peripheral blood iNKT, together with a Th1 bias. A clinical trial involved 10 children undergoing OIT for cow’s milk allergy found that the treatment not only enabled the safe and effective reintroduction of milk but also confirmed a significant increase in peripheral blood iNKT cells.[39] An early study demonstrated that the percentage of IL-12+ monocytes increased after 3 months of rush AIT in AR/AA patients.[36] A recent study in SCIT with allergoids to birch and/or grass found increased percentage of intermediate monocytes and reduced non-classical monocytes, together with increased plasmacytoid DCs and decreased CD141+ myeloid DCs.[31] Allergoid-mannan conjugates are able to reprogram monocytes into tolerogenic DCs by metabolic and epigenetic rewiring.[40] This plasticity of innate immune cells might suggest the involvement of trained immunity in the efficacy of AIT.[41] AIT inhibits the aggregation and activation of MCs, basophils, and eosinophils in the mucosa[4] and the infiltration of MCs in the skin.[42] Successful pollen immunotherapy is associated with inhibition of seasonal increases in both nasal c-Kit+ mast cells and eosinophils.[43] The molecular mechanisms involved in allergen-specific desensitization of MCs are poorly understood.[44] Histamine 2 receptors (H2R) on basophils can selectively suppress high-affinity IgE receptor (FcεRI) that might be closely associated with the very early desensitization effect of AIT.[45] It was shown that grass and birch pollen SCIT significantly decreased seasonal increase in basophils and eosinophils in the epithelium, and prevented the increase of serum eosinophilic cationic protein.[46,47] The role of airway epithelial cells in AIT includes the restoration of epithelial barriers, enhanced antiviral immunity, and the reduced production of proinflammatory cytokines. Experiments in asthma mice models showed that AIT restored airway epithelial barrier integrity by attenuating allergen-induced airway epithelial endoplasmic reticulum (ER) stress and epithelial apoptosis.[48] Experimental study in in vitro cultured human nasal epithelial cells suggested that IL-10 secreted by IL-10+ ILC2s may mediate the restoring effect of AIT on airway epithelial barrier.[34] AIT has been shown to effectively reduce the risk of exacerbations and lower respiratory tract infections in both seasonal and perennial AA,[49] which may be due to increased antiviral immunity.[50] As for the effect on alarmins, it is reported in asthma mouse models that AIT significantly decreased the level of IL-25 in the bronchoalveolar lavage fluid (BALF),[48] but not IL-25, IL-33, and TSLP in the lung tissue.[51] Transcriptome profile analysis showed that grass pollen SCIT decreased IL-25 production in PBMCs from AR patients.[13] AIT increases allergen-sIgE, IgA, IgG, and IgD antibodies, representing the intermediate effects of AIT.[52] The allergen-sIgE increases transiently followed by a gradual decrease in the next few years.[53] Allergen-specific IgG1 (sIgG1)/IgG4 and IgA1 and IgA2 levels increase in serum or local mucosa at 2–6 months after the initiation of AIT.[54] Moreover, SCIT induces a higher level of allergen-specific IgG (sIgG) compared to SLIT.[55] SCIT induces primarily sIgG, whereas SLIT induces mainly allergen-specific IgA1/IgA2.[56] IgG and IgA antibodies to these important IgE epitopes can be induced by allergen-specific immunotherapy or by passive immunization. These will lead to competition with IgE for binding with the allergen and prevent allergic responses.[53] High affinity allergen-sIgG can inhibit IgE-mediated cell activation by direct neutralization of the allergen or engagement of the inhibitory receptor FcγRIIb, which blocks IgE signal transduction by recruitment of the inositol phosphatase.[57] In addition, co-engagement of FcεRI and FcγRIIb by IgE–IgG–allergen immune complexes causes internalization of receptor-bound IgE, resulting in desensitization of the cells.[57] For IgA, it was shown that polymeric IgA2 can sensitize monocytes to produce IL-10 to induce tolerance following AIT.[58] AIT has been shown to increase pollen-specific IgD levels in the serum and lymph nodes of patients with AR.[59] Moreover, in HDM-sensitized AA patients, AIT elevates serum Der p 2-specific IgD levels, which positively correlated with asthma control.[60] These findings indicate that allergen-specific IgD might contribute to immunotolerance induced by AIT and could be a potential biomarker for the efficacy of AIT. Novel Allergen Vaccines Most of the currently available AIT vaccines are based on allergen extracts from natural allergen sources.[61] During the last 30 years, novel vaccines with higher efficacy, less frequent injections, and less side effects have been developed.[62] More types of allergen vaccines emerge or are under investigation with the identification of different components of allergens [Figure 2].[63] SCIT with purified natural major allergen molecules, such as Bet v 1[64] and Alt a 1,[65] was effective in patients with allergic rhino-conjunctivitis (ARC) and AA. In AA patients, recombinant Bet v 1 was shown to be equivalent to SCIT with natural birch pollen extracts and purified natural Bet v 1, with the additional advantages of inducing higher levels of blocking IgG and avoiding sensitization to minor allergens.[64] A mix of recombinant timothy grass pollen allergens for SCIT is effective and safe in patients with allergic rhinoconjunctivitis with or without asthma.[66] SCIT with recombinant Alt a 1 could also alleviate asthma progression and had a regulatory effect on Tfh and Breg cells in an Alternaria-induced asthmatic mouse model.[67] Novel vaccines under research for AIT. Several types of novel vaccines are under research to increase efficacy and safety of AIT, such as natural/recombinant allergen molecules, recombinant hypoallergenic derivates/fusion proteins, VNP-coupled allergens, transgenic rice-based peptide vaccines, recombinant sIgG blocking antibodies, etc. AIT: Allergen immunotherapy; sIgG: Allergen-specific immunoglobin G; VNP: Virus-like nanoparticles. The hypoallergenic vaccines based on recombinant allergens by genetic engineering or chemical modification emerge to reduce the incidence of IgE-mediated adverse reactions.[68] Typically, the fusion protein is comprised of a non-allergenic carrier protein and non-allergenic peptides derived from the IgE epitopes of allergens,[69] for example, the hypoallergenic fusion vaccine BM32 developed from 4 recombinant non-allergenic peptides of timothy grass pollen allergens fused to hepatitis B preS protein. It can induce sIgG with minimal IgE- and T cell-mediated adverse reactions.[70] A multicenter randomized controlled trial (RCT) lasting for 2 grass pollen seasons indicated that BM32-SCIT improved seasonal allergy symptoms in both treatment years, increased sIgG and reduced the seasonal increase of sIgE levels in the second year.[71] Similar effect was observed in another RCT during 2 courses, in which BM32 AIT could induce a non-inflammatory, continuously increasing sIgG4 response (year 2 >year 1), with low stimulation of allergen-specific T cell and cytokine responses but without IgE reactivity.[72] Moreover, far fewer injections of BM32 were needed to induce a comparable sIgG response precisely directed to the IgE binding sites of the allergens compared to extract-based vaccines.[73] Virus-like particle (VLP)-coupled allergens have reduced allergenic activity and enhanced immunogenicity in preclinical experiments. A VLP conjugated with Der p 2 reduced IgE reactivity, induced a substantial production of blocking sIgG, and prevented the development of allergic response to HDM in mice.[74] A VLP vaccine consisting of hepatitis B core antigen and Chenopodium album allergen 3-derived peptide was found to lack IgE-binding capacity and basophil degranulation activity, and AIT with this vaccine induced high level of sIgG and specific Th1 cell response in mice.[75] Virus-like nanoparticles (VNP) expressing shielded version of major mugwort pollen allergen Art v 1 were hypoallergenic and efficient by inducing a Th1/Treg-dominated cytokine response, increasing Foxp3+ Treg numbers in lungs in mice.[76] Transgenic rice-based peptide vaccines were potential candidates for pollen AIT, enabling OIT for respiratory allergies. A rice-based oral AIT vaccine for Japanese cedar (JC) pollinosis contains 7 linked human predominant T cell epitopes derived from Cry j 1 and Cry j 2 that are specifically expressed in the endosperm of transgenic rice seed.[77] Oral AIT with transgenic rice seeds to the participants for 24 weeks in JC pollen seasons significantly reduced specific T cell responses and improved medication scores and quality of life during the second season of administration.[78] Another transgenic rice-based vaccine was generated by depositing a chimeric molecule called tree pollen chimera 7 created by DNA shuffling of Bet v1 family sequences from birch, alder and hazel and could suppress birch pollen-induced AC in mice.[79] Besides, passive immunotherapy with the recombinant Fel d 1-specific IgG2 and IgG4 antibodies effectively alleviated cat allergy by neutralizing allergens and suppressing allergic responses.[80] Biomarkers for Assessing and Predicting the Efficacy of AIT At present, biomarkers for predicting and assessing the efficacy of AIT can be divided into 7 categories, including IgE, IgG subtypes, serum inhibitory activity of IgE, activation of basophils, cell markers, cytokines and chemokines, and in vivo biomarkers.[81] A previous study indicated that sIgE/total immunoglobulin E (tIgE) ratio can predict the ultimate therapeutic outcome of AIT, and an sIgE/tIgE ratio >16.2% was associated with a significant clinical therapeutic effect of AIT, and increased the likelihood of sIgG4 production which can effectively inhibit IgE-mediated reactions and control clinical symptoms.[82] However, this conclusion need to be confirmed with large-scale double-blind controlled studies. IgG2, a high-affinity antibody, is associated with repeated antigen exposure and can reflect the high mutation load in the variable region of IgG.[83] A study of SLIT with pollen tablets found that patients with ryegrass pollen allergy had increased serum allergen-specific IgG2 (sIgG2) levels after 3 years.[84] A 1-year study of SLIT with HDM revealed that the responders demonstrated a more substantial elevation in sIgG2 levels, which were positively correlated with sIgE response.[85] This result indicates that changes in the levels of allergen-sIgE and sIgG2 may be used in combination to monitor the efficacy and aid in medical decisions on continuation and/or adjustment of AIT. SIgG4 can competitively inhibit the binding of allergens with IgE on effector cells, and attenuate IgE-mediated hypersensitivity reactions.[86] Nevertheless, numerous studies have indicated that sIgG4 levels do not correlate with the efficacy of AIT; instead, they serve as an indicator of patient adherence. The higher the sIgG4 level, the better the patient’s adherence to AIT.[54] sIgG1 and sIgG4 were initially detected in the serum of individuals undergoing AIT with HDM and grass pollen, and sIgG1 was believed to be the primary antibody involved in the early immune response to AIT.[87] IgG1 could also block the binding of IgE to MCs and basophils, and was the main antibody responsible for the early effects of AIT.[88] However, whether sIgG1 can accurately reflect the efficacy of AIT is still unknown. IgE blocking factors (IgE-BF) refer to various factors detected by Advia Centaur that can inhibit the binding of IgE to allergens, thereby preventing allergic reactions and clinical symptoms; this inhibition is mediated by sIgG4.[89] Several studies have shown a correlation between symptom score, salvage medication score, and IgE-BF. However, the availability of IgE-BF is limited due to the discontinuation of the Advia Centaur instrument.[90] IgE-facilitated allergen binding (IgE-FAB) assay measures the binding capacity of the allergen-IgE complex to B cells expressing the low affinity IgE receptor FcεRII using flow cytometry, which can reflect the ability of B cells to present antigens to T cells.[91] Serum inhibitory activity after AIT was negatively correlated with the combined symptoms and palliative drug scores.[92] Another study also revealed a significant correlation between clinical manifestations and IgE-FAB during AIT maintenance.[93] HDM-specific IgE-FAB thresholds reduced after 16 weeks of SLIT with HDM, and HDM-sIgG4 was associated with HDM-specific IgE-FAB throughout the treatment.[94] However, it is unknown whether there are differences in IgE-FAB levels between individuals who respond well to AIT and those who do not, indicating the necessity for further research to validate its efficacy.[90] Basophil activation test (BAT) measures the degree of degranulation following stimulation with allergen by flow cytometry.[95] Currently, the activity of basophils can be assessed by the expression levels of surface markers, such as CD63 and CD203.[96] Whether the activity of basophils can predict the efficacy of AIT is controversial. Three years of tree pollen AIT significantly decreased the activity of basophils.[97] At the early stage of AIT, the decrease of basophil sensitivity predicted the extent of alleviation of allergic symptoms in allergic patients.[55] However, other study reported that the degree of basophil activation is not reduced in patients with successful AIT.[98] In recent years, more studies have confirmed that the expression of CD63 is reduced following AIT, indicating that BAT can be used as a potential indicator for the efficacy of AIT.[99] In 2020, the Oral Alpan team suggested that BAT can serve as a crucial indicator for diagnosing some allergic diseases , predicting and monitoring AIT.[100] Profound changes can be observed in different types of immune cells, including their composition, activity, and cytokine secretion, but most of them are difficult to measure during AIT because of the technical complexes, the high costs and the uncertainty of their accuracy. Currently, only the numbers and percentages of peripheral blood eosinophils are routinely measured in clinical practice. Elevated eosinophils in serum and sputum are critical biomarkers of type 2 airway inflammation. A high eosinophilic response to natural and experimental exposure to allergens may predict a good response to AIT.[101] Both SCIT and SLIT can increase the frequency of Tregs, which is associated with improved clinical symptoms.[82,102] Similarly, the number of Bregs increased in patients responding well to AIT with venom and HDM.[26,103] During 2 years of HDM-AIT, an increase in Der p 1-specific IgG4+ B cells and IL-10+ and IL-10+ IL-1RA+ Bregs are significantly correlated with improved clinical symptoms.[26] However, more direct correlations between symptom indicators and the numbers and activities of Tregs and Bregs are needed to establish their role as biomarkers for AIT efficacy. Four months of grass pollen SLIT only upregulated DCregs in patients with improved nasal conjunctivitis symptoms.[104] An increase in plasmacytoid DCs and a decrease in CD141+ myeloid DCs were observed in the first year of AIT, whereas the number of CD1c+ myeloid DCs was reduced.[31] The role of different subsets of DCs, such as DC1, DC2 and DCregs as biomarkers for AIT efficacy needs further clarification. Several studies show AIT helps restore the balance between Tfh cells and Tfr cells, which is associated with AIT efficacy.[22,105] Specifically, AIT increased the ratio of Tfr/Tfh[105] and Tfr/Tfh2,[22] suggesting Tfr and Tfh cells might be potential therapeutic targets and biomarkers in AIT. Changes in serum Th2 cytokines IL-4, IL-5, IL-9, and IL-13 levels during AIT do not directly correlate with clinical outcomes.[106] However, leukocyte immunoglobulin-like receptor A5 (LILRA5) and C-C motif chemokine ligand 25 (CCL25) were found at lower levels in patients with marked clinical improvement compared to the low responders with HDM immunotherapy, suggesting their potential roles as biomarkers of AIT.[107] Allergen provocation tests (APT), including conjunctival, nasal, bronchial provocation test, and allergen exposure chambers (AEC), are the gold standard for the diagnosis of allergic diseases.[108] These provocation tests can also be used to evaluate the success of AIT in clinical trials.[6] However, APT are not exactly the same as natural exposure and are not substitutes for symptoms assessment or rescue medication usage during natural allergen exposure in clinical trials. Clinical Outcome Measures for AIT in IgE-Mediated Allergic Diseases Clinically relevant parameters used to assess the outcomes of AIT include symptoms scores, target organ function, number of exacerbations, and reduced need for controller medication. It also emphasizes evaluation within the context of a stepwise reduction in controller medication.[109] The effectiveness of AIT is demonstrated through early efficacy (observed after initial treatment completion), sustained efficacy (efficacy during treatment), long-term efficacy (duration of efficacy after treatment completion), and preventive efficacy (preventing progression from rhinitis to asthma and preventing new sensitization).[110] A European Academy of Allergy & Clinical Immunology (EAACI) position paper recommended 8 domains for quantifying clinical outcomes of AIT in asthma, including exacerbation rate, lung function, ICS withdrawal, symptoms and medication use, questionnaires, bronchial/nasal provocation, AEC, and biomarkers.[111] Reduction in asthma exacerbations is also used to assess the effect of AIT, including the frequency of exacerbations per patient, the number of patients with at least 1 exacerbation or the time to the first asthma exacerbation upon reduction or withdrawal of ICS.[112] The definition of the severity of exacerbation is inconsistent, thus only few studies have used severity of exacerbation as a primary outcome of AIT in asthma. The parameters of lung function, such as forced vital capacity (FVC), FEV1, peak expiratory flow (PEF), maximal expiratory flow (MEF) 25, MEF 50, MEF 75, and forced expiratory flow 25–75, can be used to evaluate the efficacy of AIT in AA. However, the lung function outcomes of current AIT trials are heterogeneous and inconclusive.[113] However, the position paper of EAACI states that small airway function is an important and sensitive indicator of the effect of asthma-associated immunotherapy.[111] The efficacy of AIT can be indicated with the significant reduction in dose or discontinuation of the medications needed to achieve disease control, as demonstrated in AIT with HDM or pollen in AR and AA patients.[114,115] The primary outcome indicators commonly used in relevant studies include percentage decrease in ICS dose for asthma control,[112] the time to the first moderate or severe asthma exacerbation during a 6-month ICS reduction/withdrawal period, and the lowest ICS dose needed to maintain adequate asthma control.[116] Questionnaires, such as total nasal symptom score (TNSS), visual analog scale (VAS), and rhinoconjunctivitis quality of life questionnaire (RQLQ), are the most common used tools for assessing symptom control in AR patients about AIT.[117] The asthma control questionnaire (ACQ)-5, asthma control test (ACT), asthma quality of life questionnaire (AQLQ), and pediatric asthma quality of life questionnaire (PAQLQ) have been used in evaluating the impact of AIT on AA.[118] Allergen challenge tests, particularly with inhaled allergens, assess responses of mucosal organs by gradually inhaling the allergen to determine the cumulative dose required to induce symptoms, reflecting an increase in threshold as a result of AIT.[119] The controlled nature of allergen challenge in laboratory settings does not fully reflect real-life conditions, where other factors such as air pollution may also play a role. As a result, AEC has been used to standardize and regulate environmental parameters like temperature and humidity and allow the precise administration of allergens to allergic patients. However, this method is not practical for clinical use due to its complexity and high cost.[120] Novel Routes of AIT Multiple administration routes have been explored and applied in clinical practice. SCIT and SLIT are the 2 widely used AIT routes, whereas epicutaneous immunotherapy (EPIT) is mainly used for AIT of FA. Intralymphatic immunotherapy (ILIT) and intratonsillar immunotherapy (ITIT, one specific type of ILIT) have emerged as innovative routes with a few studies reporting their effects. We listed different AIT administration routes in Table 1.[6,121–124] Table 1Comparison of different AlT administration routes for aeroallergens.AIT routesSCITSLITEPITILITVaccine formsSubcutaneous injectionsSublingual drops or tabletsEpicutaneous delivery system[121]Intralymphatic injections (inguinal LNs, anterior cervical LNs, and tonsil)[122]Year of initiation[6,123]1911199820092008Key mechanismsInducing immunotolerance, immune deviation from Th2 to Th1, increase of regulatory immune cells (Tregs, Bregs) and cytokines (IL-10, TGF-β), production of blocking antibodies (sIgG and IgA)Similar to SCIT and oral mucosal immune responseTaking advantage of the high numbers of resident DCs in the skin to facilitate allergen processing to induce immunotoleranceDirectly targeting the peripheral immune system to induce immunotoleranceIndicationsAR/ARC, AA, AD associated with aeroallergen sensitivitySame to SCITMainly for food allergy (such as peanut allergy), ARC (studied in RCTs)ARC, AA (studied in RCTs)Course3–5 years in total, including build-up phase and maintenance phaseSame to SCIT3 months, with 12 patches applied at weekly intervals3 months, with only 3 (intra-LNs) or 6 (intratonsillar) injectionsAdvantages[6,121–124]Efficacy demonstrated by a large amount of evidence, application for the most types of aeroallergens (dust mites, pollens, fungi, cockroach, dander, etc.), effective for multi-allergies with mixed extracts, and inducing long-term toleranceEvidence-based efficacy for dust mites and pollens, non-invasive, high safety profile, and convenient for long-term useNon-invasive, high safety profile, shorter course, proven efficacy for food (peanut) allergy, and potentially effective for aeroallergens (pollens)Much fewer injections, shorter course, accelerated immunotolerance, safe, and potentially effective for aeroallergens (dust mites)Disadvantages[6,121–124]More visits and injections, invasive, relatively common local reactions, higher risk of systemic reactions even fatal anaphylaxis though rare, and poor adherenceRequiring higher doses, lower long-term efficacy for tree pollens (vs. SCIT), and possible local/systemic reactions (EoE)Limited data for aeroallergens, skin preparation by tape stripping, lower allergen bioavailability, and uncertain long-term efficacyLimited data, invasive, mostly ultrasound-guided, lacking appropriate extracts, ineffective for some aeroallergens (tree pollens), uncertain efficacy, uncertain safetyAvailabilityWidely used in clinical practice with standardized and/or native allergen vaccinesAvailable in clinical practice for common aeroallergens (dust mites, pollens)Unavailable for routine practice, and only used in clinical studiesUnavailable for routine practice, and only used in clinical studiesAA: Allergic asthma; AD: Atopic dermatitis; AIT: Allergen immunotherapy; AR: Allergic rhinitis; ARC: Allergic rhinoconjunctivitis; Bregs: Regulatory B cells; DCs: Dendritic cells; EoE: Eosinophilic esophagitis; EPIT: Epicutaneous immunotherapy; IgA: Immunoglobulin A; IL-10: Interleukin-10; ILIT: Intralymphatic immunotherapy; LNs: Lymph nodes; RCT: Randomized controlled trial; SCIT: Subcutaneous immunotherapy; sIgG: Specific Immunoglobulin G; SLIT: Sublingual immunotherapy; TGF-β: Transforming growth factor-beta; Th1: T helper cell type 1; Th2: T helper cell type 2; Tregs: Regulatory T cells. Comparison of different AlT administration routes for aeroallergens. AA: Allergic asthma; AD: Atopic dermatitis; AIT: Allergen immunotherapy; AR: Allergic rhinitis; ARC: Allergic rhinoconjunctivitis; Bregs: Regulatory B cells; DCs: Dendritic cells; EoE: Eosinophilic esophagitis; EPIT: Epicutaneous immunotherapy; IgA: Immunoglobulin A; IL-10: Interleukin-10; ILIT: Intralymphatic immunotherapy; LNs: Lymph nodes; RCT: Randomized controlled trial; SCIT: Subcutaneous immunotherapy; sIgG: Specific Immunoglobulin G; SLIT: Sublingual immunotherapy; TGF-β: Transforming growth factor-beta; Th1: T helper cell type 1; Th2: T helper cell type 2; Tregs: Regulatory T cells. ILIT delivers allergens directly to lymph nodes to enhance targeted immunomodulation, primarily investigated for AR and mild AA.[125] Preliminary data in pollen-allergic patients with AR show trends toward reduced nasal symptom scores and medication use, though evidence remains limited.[126] For AA, the only RCT enrolled pollen-allergic young adults with mild AA and concurrent AR, but nasal provocation test responses to birch/timothy allergen did not reach statistical significance.[127] Multiple meta-analyses have shown that ILIT demonstrates efficacy in improving symptoms and objective indicators of AR, particularly for grass pollen and mixed allergens, with acceptable short-to-medium term outcomes but limited long-term effectiveness.[128] ILIT’s targeted delivery minimizes systemic exposure to allergens, thereby conferring a favorable safety profile. Reported adverse events are mild to moderate, including transient local lymph node tenderness, injection-site erythema, and rare mild allergic reactions (e.g., urticaria).[128,129] However, long-term safety data (e.g., >2 years) are lacking, and potential risks in severe asthma patients remain unevaluated. ITIT is a minimally invasive novel route that delivers allergens directly to tonsillar mucosal-associated lymphoid tissue (MALT), a key site for mucosal immune regulation.[130] At present, there are relatively few studies on intratonsillar injections. A study of 120 AR patients who randomly received ITIT (3 intratonsillar allergen injections over 2 months) or SCIT (1 year), demonstrated that ITIT is superior and faster in symptom relief, especially in younger patients, while requiring markedly fewer doses and injections than SCIT, with no serious adverse events reported.[130] Another RCT also demonstrated that intratonsillar injection of HDM extract was safe and effective for AR patients.[131] In this study, ITIT upregulates allergen-specific IgG4 and Tregs while suppressing Th2-mediated inflammatory responses.[131] Despite these promising signals, large-scale RCTs are urgently needed to confirm its efficacy in AR and AA, standardize dosing protocols, and evaluate the sustainability of induced tolerance. Additionally, Gómez Medellín et al[132] developed a rapid, safe, and effective novel AIT route called liver-target AIT (LIT) in an animal model. This innovative LIT has been shown to rapidly induce antigen-specific tolerance in preclinical mouse models of allergic airway disease using mannosylated allergens. LIT has been found to ameliorate clinical, pathological, and serological features and to offer protection dependent on antigen-specific Treg cells against Der p 1. In sensitized mice, LIT provided year-long control of AA symptoms without additional intervention, showing great promise for translating to the treatment of human AR and AA.[132] Effects of AIT on AA Eight RCTs have investigated the safety and efficacy of AIT in AA over the last 10 years [Table 2].[133–140] Two studies have evaluated the preventive effect of AIT on incidence of asthma. SLIT with HDM in children decreased the asthma risk at 6 years of age by 10.6%, yielding a number needed to treat (NNT) of 10 to prevent 1 case of asthma.[141] Another RCT reported an NNT of 12 to prevent asthma symptoms in 1 additional child.[142] Virchow et al[136] demonstrated that the 6 standardized quality-house dust mite (SQ-HDM) and 12 SQ-HDM SLIT tablets decreased moderate-to-severe asthma exacerbations by 9% and 10%, respectively, corresponding to NNTs of 11 and 10. Concerning asthma medication use, 3 RCTs provide consistent evidence supporting the efficacy of AIT. Devillier et al[137] reported that the incidences of exacerbations requiring oral corticosteroids with antibiotics were similar in the active treatment group (1.6%) and the placebo group (2.5%). Another study found that after 3 years of SCIT, 28.9% (13/45) of children in the SCIT group successfully ceased ICS compared with 20.0% (9/45) in the control group.[143] De Blay et al[139] observed an ARR of 55% and an NNT of 1.82 for ICS dose reduction with 6 SQ-HDM SLIT compared with placebo. Table 2AIT for allergic asthma over the past 10 years: randomized controlled, clinical trials.Author/Year/CountryStudy design (SCIT or SLIT)AgeNumber of patientsAllergenInclusion criteriaPrimary outcome measureMain findingsDe Vos et al[133]/2021/USAAsthma standard treatment ± 3-year multiple allergen SCIT<4 yearsSCIT 35, placebo 23Pollen, dust mite, cockroach, mouse, cat, and dogPhysician-diagnosed asthma or at least 2 lifetime episodes of wheezing and 1 major or 2 minor criteriaAsthma medication and symptom scoresWith the exception of asthma-related quality of life, AIT was ineffective in improving asthma outcomes in inner-city children <4 years of age.Alviani et al[134]/2020/UKHDM or saline as placebo, Bid, 12-month SLIT5-monthSLIT 58, placebo 53HDMAt high risk of atopy ( ≥2 first-degree atopic relatives) but with negative SPT resultsAsthma prevalence at 6 years oldEarly-life administration of HDM-SLIT may prevent childhood asthma.Valovirta et al[135]/2018/Europe3 years SLIT of SQ grass pollen tablet, 2 years of follow-up5–12 yearsSLIT 398, placebo 414Grass pollenMono- or poly-grass pollen ARC without asthmaAsthma onsetSLIT reduced the risk of experiencing asthma symptoms and using asthma medication.Virchow et al[136]/2016/GermanyPlacebo or HDM SLIT tablet (6 SQ-HDM or 12 SQ-HDM) in addition to ICS.17–83 yearsPlacebo 277, 6 SQ-HDM tablet 275, 12SQ-HDM tablet 282HDMHDM-related asthma not well controlled by ICS or combination products, and with HDM allergy-related rhinitisTime to first moderate or severe asthma exacerbation during the ICS reduction period.HDM SLIT improved time to first moderate or severe asthma exacerbation during ICS reduction, with an estimated absolute reduction at 6 months of 9–10%.Devillier et al[137]/2015/France12 months of SLIT with HDM extracts or a placebo16–50 yearsActive treatment 322, placebo 162HDMWell-controlled, persistent asthmaAEs and ADRsHDM-SLIT was safe and well tolerated in adult patients with mild-to-moderate, persistent asthma.Hui et al[138]/2014/China3 years of SCIT + ICS; control group: ICS only5–14 yearsSCIT+ICS 45, ICS+ placebo 45HDMMild to moderate HDM-triggered AA ± ARThe mean daily dose of ICSs, asthma symptom scores, PEF, SPT, sIgESCIT with HDM alleviates asthma symptoms and reduces ICS dose.De Blay et al[139]/2014/Denmark, Germany, Italy, Spain, UK, Sweden, France and PolandSLIT QD with 1, 3 or 6 SQ-HDM or placebo≥14 years1 SQ-HDM 151, 3 SQ-HDM 151, 6 SQ-HDM 151, placebo 151HDMMild–moderate HDM-allergic asthmaICS reduction, AQLQ and ACQSQ HDM SLIT-tablet increases asthma control (reduced ICS dose and ACQ score) and improves quality of life.Wood et al[140]/2014/USA and UKFour pilot studies: two open-label studies to assess the safety (SLIT); two RCTs to assess efficacy (adults and children; SLIT)5–54 yearsBioCSI 1:SLIT 28, placebo 26BioCSI 2:high-dose 30, low-dose 31, placebo 28CockroachCockroach allergy-related asthmaThe change from baseline in cockroach-sIgE and specific IgG4 levels over the 6 months of treatmentSCIT is immunologically more active than SLIT, especially with regard to IgG4 levels and blocking antibody responses. No safety concerns.AA: Allergic asthma; ACQ: Asthma control questionnaire; ADRs: Adverse drug reactions; AEs: Adverse events; AIT: Allergen immunotherapy; AQLQ: Asthma quality of life questionnaire; AR: Allergic rhinitis; ARC: Allergic rhinoconjunctivitis; Bid: Bis in die; HDM: House dust mite; ICS: Inhaled corticosteroids; IgG4: Immunoglobulin G4; PEF: Peak expiratory flow; QD: Quaque die; RCTs: Randomized controlled trials; SCIT: Subcutaneous immunotherapy; sIgE: Specific immunoglobulin E; IgG4: Immunoglobulin G4; SLIT: Sublingual immunotherapy; SPT: Skin prick test; SQ: Standardized quality. AIT for allergic asthma over the past 10 years: randomized controlled, clinical trials. AA: Allergic asthma; ACQ: Asthma control questionnaire; ADRs: Adverse drug reactions; AEs: Adverse events; AIT: Allergen immunotherapy; AQLQ: Asthma quality of life questionnaire; AR: Allergic rhinitis; ARC: Allergic rhinoconjunctivitis; Bid: Bis in die; HDM: House dust mite; ICS: Inhaled corticosteroids; IgG4: Immunoglobulin G4; PEF: Peak expiratory flow; QD: Quaque die; RCTs: Randomized controlled trials; SCIT: Subcutaneous immunotherapy; sIgE: Specific immunoglobulin E; IgG4: Immunoglobulin G4; SLIT: Sublingual immunotherapy; SPT: Skin prick test; SQ: Standardized quality. In real-world studies, 9 studies reported the disease modification effects of AIT on asthma. The REACT study followed up 14,614 asthma patients with 1:1 AIT and control for 9 years, and found that AIT significantly reduced asthma prescriptions, severe asthma exacerbations and respiratory tract infection, and the effects maintained for a long time after treatment cessation.[144] Another study revealed that HDM-AIT reduced the asthma prescriptions by 10.8% (95% CI: 2.2–18.6%, P = 0.015) up to 6 years after AIT cessation.[145] AIT also reduced the medication dose in birch pollen-associated asthma.[146] The real-word studies on the efficacy of AIT in asthma over recent years are listed in Table 3.[141–152] Table 3Real-world studies of AIT for allergic asthma over the past 6 years.Country/Author/YearData sourceAllergenAdministration methodAge (years)Number (AIT/control)Inclusion criteriaPrimary outcome measureMain findingsGermany/Fritzsching et al[142]/2021German health insurance fund database (BKK); 2007.1.1–2017.12.31UnspecifiedUnspecifiedUnspecified14,614/14,614≥2 consecutive prescriptions of the same AIT and confirmed diagnosis of AR and/or asthmaAR prescriptions in each follow-up yearAIT showed longer-term and sustained effectiveness in reducing asthma exacerbations and pneumonia.Spain/Florido-López et al[145]/202011 Spanish centers; 2018.9–2019.7Olive pollenSCIT5–6589/42Patients with seasonal asthma and/or AR, caused by olive or grass/olive pollensThe number of unscheduled visits to a physician or healthcare center due to allergic disease during the pollen seasonOlive pollen AIT reduced visits to the healthcare center/emergency room and the use of asthma medication during the pollen season. It was safe and effective in olive pollen-induced asthma.Korea/Rhyou and Nam[146]/2020Dong-A University Hospital; 2000–2015UnspecifiedSCIT≥1848/69Positive on skin prick test and/or ImmunoCAP to common inhalant allergens, had used ICS for ≥1 yearChanges in the ICS doseLong-term maintenance AIT helps to spare ICS dose and achieve better control in asthma.Germany/Wahn et al[144]/2018German longitudinal prescription database (LRx, IQVIA); 2009.6–2017.2Birch pollenSCIT&SLIT≥59001/45,005Received treatment in ≥2 successive 3-tree pollen seasonal cycles, had ≥1 defining AR prescription and/or ≥2 defining asthma prescriptionsAR/asthma progression 2–6 years after active treatment cessationBirch pollen AIT reduced AR/asthma medication intake and the risk of new-onset asthma medication use on-treatment, and showed benefits up to 6 years post-treatment cessation.Germany/Jutel et al[143]/2020German longitudinal prescription database (LRx, IQVIA); 2008.1–2017.2HDMSCIT5–502350/64,740≥2 relevant mite AIT prescriptions in 2 different successive seasonal cyclesAnnual number of AR/asthma/conjunctivitis prescriptions, and the asthma occurrence after the AR index dateSCIT with HDM mite allergoid significantly reduced AR/asthma medications and the odds of asthma in the treated group were 19% lower than in the control group.France/Demoly et al[147]/2024The Stallergenes Greer’s dispensing registry and the French national health data system SNDS; 2010.1.1–2013.12.31UnspecifiedSLIT≥5112,492/333,082≥1 dispensation of SLIT liquid, ≥2 years of follow-up after the last SLIT dispensationThe occurrence of new AA events over the study periodSLIT-liquid reduced the risk of asthma onset/worsening, substantiating AIT as a causal treatment option for respiratory allergies.Germany/Schmitt[148]/2020A statutory health insurance in Germany (AOK PLUS); 2005.1.1–2014.12.31UnspecifiedSCIT&SLIT≥124111/35,056Be diagnosed with asthma ≥ twice in outpatient care, had received ≥2 prescriptions of SABA, ICS or combinations of ICS/LABA within 4 consecutive quartersProgression of asthma severity over time, according to the GINAAsthma patients treated with AIT are less likely to experience progression of asthma severity than those without AIT.Germany/Jutel et al[149]/2024German longitudinal prescription database (LRx, IQVIA); 2009.1–2013.2HDMSCIT5–70892/2676Treatment in ≥2 successive calendar years with the native depot HDM SCIT product, received ≥2 prescriptions for ICS, ICS/LABA, or LTRA during the previous 12 monthsThe number of prescriptions for AR/asthma medication, the risk of new-onset asthma, and the time to onset of asthmaSCIT with native HDM products reduced AR/asthma progression after ≥ 2 years of treatment, the effects lasted for up to 6 years after treatment termination, and AIT reduced the risk of asthma onset, starting after 15 months of treatment.Germany/Zielen et al[150]/2018German longitudinal prescription database (LRx, IQVIA); 2009.1–2016.2Grass pollenSLIT≥52851/71,275SLIT tablet prescription in ≥2 successive treatment cycles, had ≥1 prescription of INS in 365 days prior to the index dateThe change over time in prescriptions of AR symptomatic medications after treatment cessation and the probability of developing new asthmaGrass pollen SLIT tablets could reduce the frequency of AR medication use and asthma onset, and inhibit asthma/AR progression.France/Devillier et al[141]/2019The IMS LifeLinkTM Treatment Dynamics database (IQVIA); 2012.3.1–2016.12.31Grass pollenSLIT≥51099/27,475Moderate-to-severe AR in 3 successive pollen seasonsThe change over time in the number of prescriptions for symptomatic AR medicationsPrescription of grass pollen SLIT tablets could reduce the dispensing of AR and asthma medications in real life.Germany/Vogelberg et al[151]/2024German longitudinal prescription database (LRx, IQVIA); 2008.1–2020.6PollenSCIT5–655959/5959Received ≥1 prescription of a symptomatic AR medication, received AIT products-treatment with ≥ 4 prescriptions in ≥3 consecutive pollen seasons between index date and end of year 5Prescription rates and prescription volumes for allergic rhinitis and asthmaReduction of anti-asthmatic prescriptions was observed. The clinical improvements of tyrosine-adsorbed AIT for asthma and allergic rhinitis could last for up to 9.5 years.Germany/Mösges et al[152]/2024German longitudinal prescription database (LRx, IQVIA); 2009.1–2013.12HDMSCIT&SLIT≥57260/21,780Initial prescription of AIT, and 2 or more seasonal cycles of AIT during the study period, without HDM-AIT at any time beforeThe number of asthma/AR prescriptions for symptomatic medication, and the time of first asthma prescriptionAIT, especially via SCIT, reduced the need of medication against AR/asthma and might delay the onset of asthma medication in AR patients.AA: Allergic asthma; AIT: Allergen immunotherapy; AR: Allergic rhinitis; BKK: Betriebkrankenkasse; GINA: Global initiative for asthma; HDM: House dust mite; ICS: Inhaled corticosteroids; INS: Intranasal corticosteroid; LABA: Long-acting β2 agonists; LTRA: Leukotriene receptor antagonist; SABA: Short-acting beta-agonist ; SCIT: Subcutaneous immunotherapy; SLIT: Sublingual immunotherapy; SNDS: Système National des Données de Santé. Real-world studies of AIT for allergic asthma over the past 6 years. AA: Allergic asthma; AIT: Allergen immunotherapy; AR: Allergic rhinitis; BKK: Betriebkrankenkasse; GINA: Global initiative for asthma; HDM: House dust mite; ICS: Inhaled corticosteroids; INS: Intranasal corticosteroid; LABA: Long-acting β2 agonists; LTRA: Leukotriene receptor antagonist; SABA: Short-acting beta-agonist ; SCIT: Subcutaneous immunotherapy; SLIT: Sublingual immunotherapy; SNDS: Système National des Données de Santé. Effects of AIT on AR AR is the most common indication for AIT.[153] Numerous high-certainty RCTs and meta-analyses have confirmed the efficacy of both SCIT and SLIT in reducing nasal symptoms and medication use while improving quality of life.[154] In 2017, the EAACI and Chinese Guidelines recommended both SCIT and SLIT for seasonal and perennial AR based on broad evidence.[155,156] Recent studies have increasingly focused on long-term outcomes, preventive effects, and real-world effectiveness. Several RCTs have demonstrated that 3 years of effective AIT can achieve disease-modifying effects and induce sustained clinical and immunological tolerance.[157] A pivotal RCT evaluating a house dust mite sublingual tablet reported that the daily combined score (reflecting symptoms and rescue medication use) was reduced by 22% compared to placebo over the first year, with benefits persisting into the second year of treatment.[158] Similarly, for seasonal AR caused by pollen, both SCIT and SLIT significantly reduce daily symptom score and daily medication score during the peak pollen season.[159,160] A 3-year RCT of grass pollen SLIT tablet with a 2-year post-treatment follow-up, found a 25–30% reduction in symptoms and medication use that was maintained for 2 years after therapy cessation, confirming the long-term clinical tolerance induction by AIT.[161] Real-world studies corroborate and extend these findings, highlighting benefits in broader, more heterogeneous patient populations. A real-world studies about a SQ grass SLIT-tablet demonstrate real-world, long-term effectiveness of AIT, complement disease-modifying evidence observed in RCTs, and highlight the importance of using newer evidence-based AIT products for tree pollen AR.[162] Furthermore, real-world evidence confirms that AIT reduces the progression of AR, decreases the risk of new allergen sensitizations,[163] and translates into substantial reductions in both direct and indirect healthcare costs.[164] Effects of AIT on AD AIT with proven aeroallergen in AD represents an evolving area of therapeutic interest. While not a first-line treatment for all AD patients, evidence supports its utility in carefully selected patients in whom exposure to specific allergens (e.g., HDM) is a documented exacerbating factor.[165] Recent RCTs have provided more rigorous data on the efficacy of AIT on AD. For HDM-sensitized AD patients, both SCIT and SLIT significantly improves disease severity scores, such as the SCORing AD (SCORAD) index or the eczema area and severity index (EASI), compared to placebo.[166,167] A meta-analysis of these trials concluded that AIT leads to a moderate reduction in AD severity and pruritus.[165] The magnitude of effect appears to be more pronounced in patients with milder AD and in those with a clear history of flare-ups linked to allergen exposure.[165] Beyond symptom reduction, successful AIT has been associated with a decreased need for topical corticosteroid use and an improved quality of life for patients and families burdened by difficult-to-control AD.[165] Previous real-world observational studies report that AIT primarily targeting respiratory allergens can lead to concurrent improvement in AD severity and stability.[168] This suggests a systemic immunomodulatory effect that benefits the skin barrier. Additionally, available evidence highlights the importance of patient selection, as outcomes are best in those with specific IgE-mediated sensitivity.[169] Current consensus guidelines now conditionally recommend AIT for HDM-sensitized patients with AD when the disease is not adequately controlled with optimal topical therapy and allergen avoidance measures.[170] Two updated real-world cohort studies from China and Germany consistently confirm the benefits of AIT for HDM- and pollen-sensitized patients. SCORAD scores and medication use were observed to decrease significantly after 6 months of AIT, confirming its therapeutic effects on the progression and onset of AD.[171,172] Effects of AIT on FA For FA, OIT is an effective desensitization and has few adverse reactions, with low-dose protocols achieving 33–74% success rates for allergens, such as peanuts, milk, eggs, and wheat in long-term follow-ups.[173] However, a landmark, first-ever, head-to-head clinical trial revealed that omalizumab monotherapy outperformed multi-allergen OIT: 36% of omalizumab participants could tolerate ≥2 g of food allergen, compared to 19% of OIT participants. This difference was primarily due to a higher rate of allergic reactions and other side effects in the OIT group, leading to a 25% discontinuation rate of treatment.[174] Effects of AIT on other diseases For venom-induced allergy, a recently published cohort study of 17 children with hymenoptera venom allergy (HVA) in Turkey confirmed that venom immunotherapy (VIT) substantially reduces the severity of sting reactions and significantly improves the quality of life of children with HVA.[175] Biologics in AIT AIT was not recommended for use in patients with severe asthma, but promising results from studies investigating the combined use of AIT and biologics suggest a new approach to exploring these treatment modalities. Currently, biologics can be categorized based on their mechanisms into anti-IgE, -IL-5, -IL-4/IL-4 receptor (IL-4R), -TSLP, and anti-IL-13 therapy.[176] Representative drugs included omalizumab, mepolizumab, dupilumab, tezepelumab, tralokinumab. Except for tralokinumab (anti-IL-13 monoclonal antibody), which failed in a phase 3 clinical trial of asthma in 2018, all the above medications are currently used in clinical practice. Massanari et al[177] investigated the effect of omalizumab as a pretreatment on systemic allergic reactions to SCIT in patients with at least moderate persistent AA. The percentage of AIT patients experiencing a systemic allergic reaction was significantly lower in the omalizumab group (13.5% vs. 26.2%), and more patients could achieve target maintenance dose (87.3% vs. 72.1%). A case series of 17 children and adolescents with severe AA found pretreatment with omalizumab made it possible for patients with severe asthma to receive AIT.[178] A recent meta-analysis showed the combination of omalizumab with AIT significantly increased the percentage of asthmatic patients reaching target maintenance dose compared to AIT alone (OR = 2.09; 95% CI:1.23–3.53; P = 0.006).[179] It has been discovered that combination of HDM-SLIT with dupilumab is beneficial to uncontrolled asthma with rhinitis.[180] Another study reported the combination of SCIT and dupilumab improved clinical symptoms in HDM-sensitized AD patients.[171] Tezepelumab was shown to enhance the effectiveness of SCIT and may facilitate tolerance following 1-year treatment in AR patients.[181] Mepolizumab in combination with AIT in asthma patients has not been reported. Currently, although the available clinical data are limited, they all suggest that combination therapy not only enhances the safety of AIT but may also improve its efficacy and even help achieve clinical remission.[182] The potential mechanisms may be attributed to a reduction in free IgE levels, leading to downregulation of FcεRI receptor expression on MCs and basophils, and consequently a decrease in AIT-induced systemic allergic reactions, as well as the synergistic inhibition of type 2 inflammatory pathways and the suppression of mast cell activation.[182] Limitations and Future Directions Despite its efficacy and potential for disease modification, the broader adoption of AIT faces significant limitations. Safety concerns, particularly with SCIT due to the risk of systemic reactions including anaphylaxis, necessitate clinic-based administration, increasing treatment burden and cost.[63] Managing polysensitized patients remains difficult, as the utility of single-allergen AIT is limited, and evidence for multiallergen formulations is still inadequate.[183] Practical barriers include the long treatment duration (typically 3–5 years), which challenges patient adherence. Compared to biologics, AIT entails lower direct costs but greater time investments and more frequent visits. Biologics offer a rapid onset of action and convenient dosing (e.g., injections every few weeks) at a higher drug cost, creating distinct trade-offs for clinical decision-making.[184] Furthermore, regional variability in the quality and standardization of allergen extracts complicates universal protocols, impacting both efficacy and safety.[185] Future work should prioritize developing predictive biomarkers for patient selection, optimizing short-course and targeted routes, such as ILIT, and clarifying synergistic roles for AIT combined with biologics in severe asthma. Conclusion In conclusion, complicated immunological changes contribute to the tolerance induction and regulating effects of AIT in allergic diseases. Novel vaccines and administration routes are evolving to enhance the efficacy and reduce the duration needed to achieve sustained tolerance following AIT. Biologicals targeting T2 inflammation in combination with AIT will reduce the adverse effects associated with AIT and synthetically inhibit T2 inflammation. Biomarkers predicting and indicating the efficacy of AIT warrant further research. Conflicts of interests None.